Please use this identifier to cite or link to this item: http://www.repositorio.ufc.br/handle/riufc/26626
Title in Portuguese: PLGA Microspheres as new strategy to improve the efficiency of venom immunotherapy
Author: Trindade, R eginaldo Almeida da
Sant’Anna, Osvaldo Augusto Brazil Esteves
Rescia, Vanessa Cristina
Bruni, Fernanda Miriani
Lopes-Ferreira, Mônica Valdyrce dos Anjos
Santos, Daiane Fernanda dos
Nicolete, Roberto
Faccioli, Lucia Helena
Araujo, Pedro Soares de
Costa, Maria Helena Bueno da
Keywords: Hipersensibilidade
Hypersensitivity
Imunoterapia
Immunotherapy
Issue Date: 2017
Publisher: Journal of Chemical and Pharmaceutical Research
Citation: TRINDADE, R. A. da et al. PLGA microspheres as new strategy to improve the efficiency of venom immunotherapy. Journal of Chemical and Pharmaceutical Research, v. 9, n. 3, p. 197-208, 2017.
Abstract: Background: Despite considerable knowledge of allergy and its physiopathology, the only treatment with long - lasting effects for bee venom (BV) allergic patients is venom immunotherapy (VIT). Its efficiency has been recognized worldwide for many years. Howe ver, some limitations still result in patient rejection and prevent its use, such as the long treatment period with a total of 30 - 80 injections administered over three to five years, the high cost of treatment, and the risk of anaphylaxis as a side effect. Objective: In order to overcome these inconveniences, a new formulation for VIT is proposed, consisting of BV encapsulated within microspheres composed of poly - lactide - co - glycolide (MS - PLGA) as a controlled delivery system. Methods: BV - MS - PLGA was prepare d by a double emulsion/solvent evaporation method and its biological efficiency was tested by ex vivo macrophage uptake stimuli and in vivo antibody production in mice. Results: BV - MS - PLGA formulations prevented inflammatory reactions by impeding direct co ntact between BV and the organism/tissue. The increased phagocytosis rate of BV - MS - PLGAs by macrophages allowed for the delivery of antigens directly to the intracellular environment. Furthermore, with the use of BV - MS - PLGAs, antibody production was compar able to traditional VIT (free BV delivered in PBS) with the advantages of protecting the organism against the deleterious effects of BV toxins and reducing the number of injections needed to produce the same protective effect. Conclusion: MS - PLGA is a prom ising controlled delivery system to deliver BV for VIT.
URI: http://www.repositorio.ufc.br/handle/riufc/26626
metadata.dc.type: Artigo
ISSN: 0975 - 7384
Appears in Collections:DFAR - Artigos publicados em revistas científicas

Files in This Item:
File Description SizeFormat 
2017_art_ratrindade.pdf495,23 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.